Hong Kong's Immuno Cure Emerges With DNA Vaccine Approach To HIV
Local Ecosystem Still Developing
Executive Summary
Hong Kong-based Immuno Cure expects its therapeutic DNA vaccine for HIV/AIDS will soon deliver early Phase I results in patients with late-stage infections, CEO Xia Jin tells Scrip in an interview, also touching on the local biotech ecosystem.